Yahoo Sports Real Madrid want Liverpool ace as priority for 2025 but plans could change if academy ace explodes
A recent report from MARCA suggests that while Real Madrid remain focused on signing Trent Alexander-Arnold, the rise of young Jesus Fortea could reshape their transfer plans.
It is no secret that strengthening the right-back and centre-back positions has become essential for Real Madrid as they look to reinforce their defensive line.
Fortea’s presence in first-team training and his recent inclusion in potential line-ups hint that the club views him as a valuable asset. This was not a surprise, as there were indications weeks earlier that Real Madrid saw Fortea as a potential backup for Lucas Vazquez.
His rapid development is promising, and he might just step up to fill the role if needed in the upcoming fixtures.
Fortea holds the key
If Carlo Ancelotti decides to give Fortea a chance, and the young talent performs well, Real Madrid could delay signing a new right-back until next summer.
This would allow the club to monitor Vazquez’s performance as his contract renewal approaches. At the same time, they would be keeping an eye on Dani Carvajal’s recovery from his injury setbacks.
The long-term goal remains Alexander-Arnold, with both the club and the player reportedly eager to work together. However, Liverpool have been clear that they are not open to selling their star player mid-season.
This situation points to Real Madrid holding off on any significant moves in January and relying on alternative solutions until the summer transfer window.
If Vazquez is unavailable, Real Madrid could turn to Eder Militao as a makeshift right-back or rely on Fortea, who is showing promise in training.
Ancelotti, impressed by Fortea’s abilities, holds the decision-making power over the youngster’s involvement.
With a packed schedule leading up to the winter break, Ancelotti’s choices regarding playing time will likely indicate whether Real Madrid intends to pursue Alexander-Arnold in the next transfer window or continue developing Fortea as a longer-term option.
